CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.
Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Chemed's (CHE) Q4 revenues grow across key segments.
Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y
by Zacks Equity Research
Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.
Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong
by Zacks Equity Research
Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.
NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.
Why Is Conmed (CNMD) Up 4.3% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.
Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
Ecolab (ECL) Earnings and Revenues Match Estimates in Q4
by Zacks Equity Research
Ecolab (ECL) sees solid segmental gains in Q4.
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
by Zacks Equity Research
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
by Zacks Equity Research
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
Bio-Techne (TECH) sees increase in revenues across key segments.
Here's Why Investors Should Buy CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
by Zacks Equity Research
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q4.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
Cardinal Health (CAH) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.